This study aims to compare the efficacy of intercalating chemotherapy (gefitinib and pemetrexed/cisplatin) and chemotherapy (navelbine/cisplatin) in completely resected NSCLC with common EGFR mutations.
Name: gefitinib, pemetrexed,cisplatin
Description: Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2Type: DrugIntercalating arm
Name: Vinorelbine, cisplatin
Description: Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3weekType: Drugchemotherapy alone arm
Description: Time from the randomization to recurrence or any cause of death.
Measure: disease-free survival Time: 5 yearsDescription: Time from the randomization to death of any cause
Measure: Overall survival Time: 5 yearAllocation: Randomized
Parallel Assignment
There is one SNP
Inclusion Criteria: 1. Completely resected non-squamous cell NSCLC with stage IIa to IIIb (excluding N3) according to Version 8 of the IASLC Staging Manual in Thoracic Oncology 2. Tumors with common EGFR mutations (19del or L858R) 3. Adequate oran function Exclusion Criteria: 1. Patients who were exposed to the chemotherapy or EGFR TKIs for NSCLC. --- L858R ---
2. Patients with interstitial lung disease Inclusion Criteria: 1. Completely resected non-squamous cell NSCLC with stage IIa to IIIb (excluding N3) according to Version 8 of the IASLC Staging Manual in Thoracic Oncology 2. Tumors with common EGFR mutations (19del or L858R) 3. Adequate oran function Exclusion Criteria: 1. Patients who were exposed to the chemotherapy or EGFR TKIs for NSCLC. --- L858R ---